| The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases HM Blevins, Y Xu, S Biby, S Zhang Frontiers in aging neuroscience 14, 879021, 2022 | 282 | 2022 |
| A novel inhibitor targeting NLRP3 inflammasome reduces neuropathology and improves cognitive function in Alzheimer’s disease transgenic mice R Kuwar, A Rolfe, L Di, H Blevins, Y Xu, X Sun, GS Bloom, S Zhang, ... Journal of Alzheimer's Disease 82 (4), 1769-1783, 2021 | 63 | 2021 |
| Discovery of second-generation NLRP3 inflammasome inhibitors: Design, synthesis, and biological characterization Y Jiang, L He, J Green, H Blevins, C Guo, SH Patel, MS Halquist, ... Journal of medicinal chemistry 62 (21), 9718-9731, 2019 | 52 | 2019 |
| CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing Z Liu, W Liu, W Wang, Y Ma, Y Wang, DL Drum, J Cai, H Blevins, E Lee, ... Proceedings of the National Academy of Sciences 120 (39), e2302878120, 2023 | 30 | 2023 |
| Discovery of carbon-11 labeled sulfonamide derivative: a PET tracer for imaging brain NLRP3 inflammasome Y Xu, Y Xu, H Blevins, Y Lan, Y Liu, G Yuan, R Striar, JS Zagaroli, ... Bioorganic & medicinal chemistry letters 34, 127777, 2021 | 18 | 2021 |
| Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity relationship studies Y Xu, Y Xu, H Blevins, C Guo, S Biby, XY Wang, C Wang, S Zhang European journal of medicinal chemistry 238, 114468, 2022 | 15 | 2022 |
| The NLRP3 inflammasome pathway: A review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front Aging Neurosci 2022; 14: 879021 HM Blevins, Y Xu, S Biby, S Zhang Trends Pharmacol Sci 43 (8), 653-68, 2022 | 11 | 2022 |
| The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases. Front Aging Neurosci 14: 879021 HM Blevins, Y Xu, S Biby, S Zhang | 9 | 2022 |
| Characterization of an extracellular polyhydroxyalkanoate depolymerase from streptomyces sp. SFB5A HM Blevins, MKD Blue, BD Cobbs, TA Ricotilli, SL Kyler, CT Shuey, ... Journal of Bioremediation & Biodegradation 9 (05), 2018 | 9 | 2018 |
| Development of bivalent compounds as potential neuroprotectants for Alzheimer’s disease L He, Y Jiang, J Green, H Blevins, S Zhang Bioorganic & medicinal chemistry letters 29 (15), 1957-1961, 2019 | 4 | 2019 |
| Mechanistic Insights of Sulfonamide‐Based NLRP3 Inhibitors for the Treatment of Neurodegenerative Diseases H Blevins, Y Xu, S Biby, S Zhang The FASEB Journal 36, 2022 | 2 | 2022 |
| Structural insights of sulfonamide-based NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization Y Xu, M Scipioni, H Blevins, S Zhang Medicinal Chemistry Research 30, 473-482, 2021 | 2 | 2021 |
| Development of NLRP3 Inflammasome Inhibitors HM Blevins | | 2022 |
| Development of NLRP3 inhibitors for Alzheimer's disease S Zhang, Y Xu, H Blevins Alzheimer's & Dementia 17, e049271, 2021 | | 2021 |
| Mechanistic insights of novel NLRP3 inhibitors as potential AD therapeutics: Nonhuman/Target identification and validation studies: Inflammation and innate immunity J Green, H Blevins, Y Xu, S Zhang Alzheimer's & Dementia 16, e037215, 2020 | | 2020 |
| Mechanistic insights of novel NLRP3 inhibitors as potential AD therapeutics J Green, H Blevins, Y Xu, S Zhang 2020 Alzheimer's Association International Conference, 2020 | | 2020 |
| Characterization of polyhydroxyalkanoate enzymatic degradation products by mass spectrometry H Blevins, S Baron ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 255, 2018 | | 2018 |
| Characterization of an extracellular polyhydroxyalkanoate depolymerase from Streptomyces sp. SFB5A S Baron, HM Blevins, BD Cobbs, M Blue, TA Ricotilli, SL Kyler, CT Shuey, ... | | 2018 |
| Journal of Bioremediation & Biodegradation HM Blevins, D M’Kala, BD Cobbs, TA Ricotilli, SL Kyler, CT Shuey, ... | | 2018 |